Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020–May 2021

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01540-1 · Cited by 1,163

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · doi:10.1101/2021.06.21.21258528 · Cited by 1,163

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101667 · Cited by 696

Variance estimation for complex surveys using replication techniques

Rust, K., & Rao, J. (1996) · Statistical Methods in Medical Research · doi:10.1177/096228029600500305 · Cited by 662

Association of Social and Demographic Factors with COVID-19 Incidence and Death Rates in the US

Karmakar, M., Lantz, P. M., & Tipirneni, R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.36462 · Cited by 580

Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020

Bajema, K. L., Wiegand, R. E., Cuffe, K. M., Patel, S. V., Iachan, R., Lim, T. W., Lee, A., Moyse, D., Havers, F. P., Harding, L., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.7976 · Cited by 272

Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study

Anand, S., Montez‐Rath, M. E., Han, J., Bozeman, J., KERSCHMANN, R. L., Beyer, P., Parsonnet, J., & Chertow, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32009-2 · Cited by 265

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265

Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020

Machalek, D. A., Vette, K., Downes, M., Carlin, J. B., Nicholson, S. R., Hirani, R., Irving, D. O., Gosbell, I. B., Gidding, H. F., Shilling, H. S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265858 · Cited by 5

Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022

Yamayoshi, S., Iwatsuki‐Horimoto, K., Okuda, M., Ujie, M., Yasuhara, A., Murakami, J., Duong, C., Hamabata, T., Ito, M., Chiba, S., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2811.221127 · Cited by 6

SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis

Malijan, G. M., Edwards, T., Agrupis, K. A., Suzuki, S., Villanueva, A. M. G., Sayo, A. R., Guzman, F. D., Dimapilis, A. Q., Solante, R., Telan, E. O., et al. (2022) · Tropical Medicine and Health · doi:10.1186/s41182-022-00468-7 · Cited by 5

COVID-19 Infections, Pandemic-Related Social and Economic Impacts, and Changes to Mental and Self-Rated Health Among Latinx Immigrant Housecleaners in New York City: The Safe and Just Cleaners Study

Baron, S., Cuervo, I., Shah, D., Gonzalez, A., Harari, H. C., & Flores, D. (2023) · American Journal of Public Health · doi:10.2105/ajph.2023.307324 · Cited by 5

Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study

Hou, C., Williams, S. A., Taylor, K., Boyle, V., Bobbett, B., Kouvetakis, J., Nguyen, K., McDonald, A., Harris, V. K., Nussle, B., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072627 · Cited by 4

The evolution and interpretation of seroprevalence of SARS‐CoV ‐2 antibodies among South African blood donors from the Beta to Omicron variant‐driven waves

Vermeulen, M., Mhlanga, L., Sykes, W., Cable, R., Coleman, C., Pietersen, N., Swanevelder, R., Glatt, T. N., Bingham, J., van den Berg, K., et al. (2023) · Vox Sanguinis · doi:10.1111/vox.13571 · Cited by 5

Minding the margins: Evaluating the impact of COVID-19 among Latinx and Black communities with optimal qualitative serological assessment tools

Binder, R. A., Matta, A. M., Forconi, C. S., Oduor, C. I., Bedekar, P., Patrone, P. N., Kearsley, A. J., Odwar, B., Batista, J., Forrester, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307568 · Cited by 5

Modelling COVID-19 in the North American region with a metapopulation network and Kalman filter

Perini, M., Yamana, T. K., Galanti, M., Suh, J., Kaondera-Shava, R. F., & Shaman, J. L. (2025) · Epidemics · doi:10.1016/j.epidem.2025.100818 · Cited by 5

Low Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory Syndrome Coronavirus 2 in a Community-Based Serological Study

McDade, T. W., Sancilio, A., D’Aquila, R. T., Mustanski, B. S., Vaught, L. A., Reiser, N. L., Velez, M. E., Hsieh, R. R., Ryan, D. T., Saber, R., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac055 · Cited by 6

Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors

Grebe, E., Yu, E. A., Bravo, M. D., Welte, A., Bruhn, R. L., Stone, M., Green, V., Williamson, P. C., Feldstein, L. R., Jones, J. M., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac318 · Cited by 5

Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA

Matias, W. R., Fulcher, I., Sauer, S. M., Nolan, C. P., Guillaume, Y., Zhu, J., Molano, F. J., Uceta, E., Collins, S., Slater, D., et al. (2023) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-022-01502-4 · Cited by 7

Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September–December 2021

Kao, S. Z., Nycz, E., Benoit, T. J., Clarke, K. E. N., & Jones, J. M. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00123-24 · Cited by 5

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in HIV-positive and HIV-negative patients in clinical settings in Douala, Cameroon

Nolna, S. K., Niba, M., Djadda, C., & Netongo, P. M. (2023) · Frontiers in Epidemiology · doi:10.3389/fepid.2023.1212220 · Cited by 4

Association of Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence and State-Issued Nonpharmaceutical Interventions: United States, 1 August 2020 to 30 March 2021

Miller, M. J., Himschoot, A., Fitch, N., Jawalkar, S., Freeman, D. F., Hilton, C., Berney, K., Guy, G. P., Benoit, T. J., Clarke, K. E. N., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac469 · Cited by 4

A Longitudinal Study of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response in a Subset of United States Blood Donors

Tonnetti, L., Dodd, R. Y., Burke, D., Saá, P., Spencer, B. R., Xu, M. J., Haynes, J. M., & Stramer, S. L. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac697 · Cited by 4

Seroprevalence of SARS-CoV-2 Antibodies in Denmark: Results of Two Nationwide Population-Based Surveys, February and May 2021

Krogsgaard, L. W., Espenhain, L., Tribler, S., Jørgensen, C. S., Hansen, C. H., Møller, F. T., Helmuth, I. G., Sönksen, U. W., Vangsted, A., Ullum, H., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s383491 · Cited by 4

Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals

Dai, Y.-C., Lin, Y.-C., Ching, L. L., Tsai, J., Ishikawa, K. M., Tsai, W.-Y., Chen, J. J., Nerurkar, V. R., & Wang, W. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04081-22 · Cited by 4

Clinical and laboratory characteristics of patients hospitalized with severe COVID-19 in New Orleans, August 2020 to September 2021

Drouin, A. C., Plumb, I. D., McCullough, M., James-Gist, J., Liu, S., Theberge, M., Katz, J., Moreida, M., Flaherty, S., Chatwani, B., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57306-5 · Cited by 4

SARS-CoV-2 vaccination in Canadian blood donors: Insight into donor representativeness of the general population

O’Brien, S. F., Goldman, M., Ehsani‐Moghaddam, B., Fan, W., Osmond, L., Pambrun, C., & Drews, S. J. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100498 · Cited by 4

Adherence to COVID ‐19 vaccination recommendations and vaccine hesitancy in US blood donors

Avelino‐Silva, V. I., Bruhn, R. L., Zurita, K. G., Grebe, E., Stone, M., Busch, M. P., & Custer, B. (2024) · Transfusion · doi:10.1111/trf.18051 · Cited by 4

The disappearing COVID-Naïve Population and comparative Roche vs. Abbott Test sensitivity: evidence from antibody seroprevalence in Milwaukee County, Wisconsin

Franchi, L., Atanasov, V. A., Stake, M., Bates, G., Osinski, K. I., Meurer, J., & Black, B. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-76946-1 · Cited by 4

Jamestown Canyon Virus Seroprevalence in Endemic Regions and Implications for Diagnostic Testing

Sutter, R. A., Calvert, A. E., Grimm, K. E., Biggerstaff, B. J., Thrasher, E., Mossel, E. C., Martin, S. W., Lehman, J. A., Saá, P., Townsend, R., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf131 · Cited by 4

Seroepidemiology and risk factors for SARS-CoV-2 infection among household members of food processing and farm workers in North Carolina

Sciaudone, M., Cutshaw, M. K., McClean, C. M., Lacayo, R., Kharabora, O., Murray, K., Strohminger, S., Zivanovich, M. M., Gurnett, R., Markmann, A. J., et al. (2023) · IJID Regions · doi:10.1016/j.ijregi.2023.03.010 · Cited by 4

SARS‐CoV‐2 seroprevalence and vaccine coverage from August to November 2021: A nationally representative survey in Mexico

Basto-Abreu, A. C., Carnalla, M., Torres‐Ibarra, L., Sánchez‐Pájaro, A., Martínez, M. R., Martínez-Barnetche, J., López-Martı́nez, I., Aparicio‐Antonio, R., Shamah‐Levy, T., Alpuche-Aranda, C. M., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29038 · Cited by 4

Seroprevalence of Anti-SARS-CoV-2 Remained Extremely Low in Taiwan Until the Vaccination Program Was Implemented

Chen, Y., Yang, M., Lai, J.-Z., Chen, J.-W., Wang, Y., Wei, S., Hou, S., Chen, C., & Wu, H.-S. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad614 · Cited by 4

Cohort profile: follow-up of a household cohort throughout five epidemic waves of SARS-CoV-2 in Rio de Janeiro, Brazil

da Silva, M. F. B., Guaraldo, L., Santos, H. F. P., Bastos, L. S., de Pina-Costa, A., Penetra, S. L. S., Moraes, I. C. V., Calvet, G. A., Fuller, T. L., Resende, P. C., et al. (2024) · Cadernos de Saúde Pública · doi:10.1590/0102-311xen152023 · Cited by 4

Impact of vaccination on SARS-CoV-2 seroprevalence rate in French blood donors: An assessment as of July 2021

Gallian, P., Slimani, A., Malard, L., Morel, P., & de Lamballerie, X. N. (2022) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2022.08.002 · Cited by 4

“Boosting” Surveillance for a More Impactful Public Health Response During Protracted and Evolving Infectious Disease Threats: Insights From the COVID-19 Pandemic

Qasmieh, S. A., Robertson, M. M., & Nash, D. (2023) · Health Security · doi:10.1089/hs.2023.0046 · Cited by 4

Influenza and COVID ‐19 vaccination in Canadian blood donors: A comparison across pre‐ and post‐pandemic periods

O’Brien, S. F., Osmond, L., Goldman, M., & Drews, S. J. (2025) · Vox Sanguinis · doi:10.1111/vox.70006 · Cited by 3

Cumulative seroprevalence among healthcare workers after the first wave of the COVID-19 pandemic in El Salvador, Central America

Nakagama, Y., Rodriguez-Funes, M.-V., Domínguez, R., Candray, K., Uemura, N., Tshibangu‐Kabamba, E., Nitahara, Y., Kaku, N., Kaneko, A., & Kido, Y. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.06.020 · Cited by 3

Seroprevalence of SARS-CoV-2 antibodies among public transport workers in Sweden

Sjörs, A., & Anund, A. (2022) · Journal of Transport & Health · doi:10.1016/j.jth.2022.101508 · Cited by 3

Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave

Dai, Y.-C., Lin, Y.-C., Ching, L. L., Tseng, A. C., Qin, Y., Nerurkar, V. R., & Wang, W. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1019490 · Cited by 3

Excess mortality in US Veterans during the COVID-19 pandemic: an individual-level cohort study

Weinberger, D. M., Bhaskaran, K., Korves, C., Lucas, B., Columbo, J. A., Vashi, A. A., Davies, L., Justice, A. C., & Rentsch, C. T. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad136 · Cited by 3

Seroprevalence trends of anti-SARS-CoV-2 antibodies in the adult population of the São Paulo Municipality, Brazil: Results from seven serosurveys from June 2020 to April 2022. The SoroEpi MSP Study

Tess, B. H., Martelli, C. M. T., Alves, M. C. G. P., Cortés, F., Bernal, R. T. I., de Souza, W. V., Luna, E. J. D. A., Rodrigues, L. D. C., Nunes, M. C., Reinach, F. D. C., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309441 · Cited by 3

Interpreting the Influence of Using Blood Donor Residual Samples for SARS-CoV-2 Seroprevalence Studies in Japan: Cross-Sectional Survey Study

Kinoshita, R., Miyamoto, S., Suzuki, T., Suzuki, M., & Yoneoka, D. (2025) · JMIR Public Health and Surveillance · doi:10.2196/60467 · Cited by 3

College Athletic Programs Thwart the Spread of SARS-CoV-2 During the COVID-19 Pandemic

O’Neal, C. S., Dixon, B. C., & Fischer, R. S. B. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.47810 · Cited by 3

Seroprevalence of SARS-CoV-2 antibodies among Jordanian citizens: A cross-sectional study of the demographic and clinical factorsthat ameliorate serum IgG concentration

Rayyan, W. A. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2022.121116 · Cited by 3

SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).

Pirón, M., Jané, M., Ciruela, P., Basile, L., Martı́nez, A., Puig, L., Bes, M., & Sauleda, S. (2022) · PubMed Central · doi:10.2450/2022.0232-21 · Cited by 3

Precision transfusion medicine in the omics era

D’Alessandro, A. (2026) · Blood · doi:10.1182/blood.2026034666 · Cited by 2

A Saliva-Based Serological and Behavioral Analysis of SARS-CoV-2 Antibody Prevalence in Howard County, Maryland

Brown, A. C., Koshute, P. T., Cowley, H., Robinette, M. S., Gravelyn, S., Patel, S. V., Ju, E. Y., Frommer, C. T., Zambidis, A. E., Schneider, E. J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02765-22 · Cited by 2

Bidirectionality between Cardiometabolic Diseases and COVID-19: Role of Humoral Immunity

Yu, E. A., Jackman, R. P., Glesby, M. J., & Narayan, K. V. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.06.003 · Cited by 2

Investigating SARS-CoV-2 Incidence and Morbidity in Ponce, Puerto Rico: Protocol and Baseline Results From a Community Cohort Study

Major, C. G., Rodríguez, D. M., Sánchez‐González, L., Rodríguez-Estrada, V., Morales-Ortíz, T., Torres, C., Pérez-Rodríguez, N. M., Medina, N. A., Alexander, N. D. E., Mabey, D. C. W., et al. (2024) · JMIR Research Protocols · doi:10.2196/53837 · Cited by 2

Increased measles and rubella seroprevalence in children using residual blood samples from health facilities and household serosurveys after supplementary immunization activities in two districts in India

Prosperi, C., Hasan, A. Z., Winter, A. K., Chaaithanya, I. K., Salvi, N., Sharma, S., Bansal, A. K., Chauhan, S., Kulkarni, R. N., Lachyan, A. S., et al. (2024) · Epidemiology and Infection · doi:10.1017/s0950268824001353 · Cited by 2

Estimated US Trends in SARS-CoV-2 Spike Antibody Concentrations and Correlation to Risk of First-Time Infections Based on Blood Donations, 2022

Jones, J. M., Grebe, E., Lartey, I., Stone, M., Spencer, B. R., Akinseye, A., Manrique, I. M., Fink, R. V., Green, V., Saá, P., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf329 · Cited by 2

Correlates of Coronavirus Disease 2019 Inpatient Mortality at a Southern California Community Hospital With a Predominantly Hispanic/Latino Adult Population

Gatto, N. M., Freund, D., Ogata, P., Diaz, L. M., Ibarrola, A., Desai, M., Aspelund, T., & Gluckstein, D. P. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad011 · Cited by 2

Contributions to the Mitigation of the COVID-19 Pandemic

Pilz, S. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac033 · Cited by 2

Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 Treatments

Money, K. M., Baber, U., Saart, E., Samaan, S., & Sloane, J. A. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.843081 · Cited by 2

Pre-Existing Population Immunity and severe acute respiratory syndrome coronavirus 2 Variant Establishment and Dominance Dynamics in the United States: An Ecological Study

Ankomah, P., Siedner, M. J., & Bhattacharyya, R. P. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac621 · Cited by 1

Serological Studies and the Value of Information

Dean, N. E., Howard, D. H., & Lopman, B. A. (2023) · American Journal of Public Health · doi:10.2105/ajph.2023.307245 · Cited by 2

Evolution of seroprevalence to SARS‐CoV‐2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross‐sectional and longitudinal studies

Musa, S., Ćatović-Baralija, E., Sawin, V. I., Nardone, A., Palo, M., Skočibušić, S., Blažević, M., Lagarija, S., Ahmetović-Karić, G., Ljuca, A., et al. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13182 · Cited by 2

Dynamics of SARS-CoV-2 infection over two epidemic waves in Manaus, Brazil: A serological study of seven thousand blood donors

Alexander, N. D. E., Dye, C., Busch, M. P., Buss, L., Junior, C. A. P., Brady, O. J., Mee, P., Abrahim, C. M. M., Crispim, M. A. E., Costa, A. G., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0308319 · Cited by 1

A population-based case–control study of COVID-19: methodological considerations on the role of testing bias

Fantin, R., Porras, C., Aparicio, A., Vanegas, J. C., Loria, V., Morera, M., Abdelnour, A., Waterboer, T., Butt, J., Pfeiffer, R. M., et al. (2025) · Journal of Public Health · doi:10.1093/pubmed/fdaf055 · Cited by 1

Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study

Choi, Y., Jacobs, D. R., Kramer, H. J., Coresh, J., Cushman, M., Reiner, A. P., Demmer, R. T., Tracy, R. P., Sun, Y., Balte, P., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.04.011 · Cited by 1

Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021

Bassal, R., Keinan‐Boker, L., Cohen, D., Mendelson, E., Lustig, Y., & Indenbaum, V. (2022) · Vaccines · doi:10.3390/vaccines10101663 · Cited by 1

A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2

Brown, E. R., O’Brien, M. P., Snow, B., Isa, F., Forleo‐Neto, E., Chan, K., Hou, P., Cohen, M. S., Herman, G. A., & Barnabas, R. V. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad271 · Cited by 1

SARS-CoV-2 seroprevalence in Nova Scotia blood donors

O’Brien, S. F., Deeks, S. L., Hatchette, T. F., Pambrun, C., & Drews, S. J. (2024) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2023-0017 · Cited by 1

Higher intraindividual variability of body mass index is associated with elevated risk of COVID-19 related hospitalization and post-COVID conditions

Yu, E. A., Bravo, M. D., Avelino‐Silva, V. I., Bruhn, R. L., Busch, M. P., & Custer, B. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01603-6 · Cited by 1

Association of SARS-CoV-2 Serology Test Result and COVID-19 Vaccination in Adults: A Multisite Cohort Study

Glanz, J. M., Palmer-Toy, D. E., Narwaney, K. J., Barrow, J. C., Bruxvoort, K. J., Kraus, C. R., Lyons, J. A., & Binswanger, I. A. (2025) · AJPM Focus · doi:10.1016/j.focus.2025.100423 · Cited by 1

Likely community transmission of COVID-19 infections between neighboring, persistent hotspots in Ontario, Canada

Mucaki, E. J., Shirley, B. C., & Rogan, P. K. (2021) · F1000Research · doi:10.12688/f1000research.75891.1 · Cited by 1

Importance of establishing antibody specificity in multisystem inflammatory syndrome in newborn during the COVID‐19 pandemic

Leslie, A. T. F. S., Saleh, M., Soni, N., Tang, P., Kallem, V. R., Tscherning, C., & More, K. (2022) · Acta Paediatrica · doi:10.1111/apa.16345 · Cited by 1

Lessons Learned from the COVID-19 Pandemic and How Blood Operators Can Prepare for the Next Pandemic

Drews, S. J., & O’Brien, S. F. (2022) · Viruses · doi:10.3390/v14102126 · Cited by 1

Low rate of detection of SARS-CoV-2 RNA in deceased tissue donors

Greenwald, M. A., Grebe, E., Green, V., Jones, A. L., Linnen, J. M., Williamson, P. C., Busch, M. P., & Kuehnert, M. J. (2022) · Cell and Tissue Banking · doi:10.1007/s10561-022-10054-0 · Cited by 1

Clinical Protection During the First Omicron Wave in Unvaccinated, Convalescent US Adults

Stone, M., Grebe, E., & Busch, M. P. (2022) · JAMA · doi:10.1001/jama.2022.10332 · Cited by 1

Development and use of a method based on the anti-N reactivity of longitudinal samples to better estimate SARS-CoV-2 seroprevalence in a vaccinated populationPreprint

Bazin, R., Rochette, S., Perreault, J., Fournier, M., Grégoire, Y., Boivin, A., Lewin, A., Germain, M., & Renaud, C. (2022) · medRxiv · doi:10.1101/2022.08.15.22278798 · Cited by 1

Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.SPreprint

García‐Carreras, B., Hitchings, M. D. T., Johansson, M. A., Biggerstaff, M., Slayton, R. B., Healy, J. M., Lessler, J., Quandelacy, T. M., Salje, H., Huang, A. T., et al. (2022) · medRxiv · doi:10.1101/2022.09.13.22279702 · Cited by 1

Real-time surveillance of international SARS-CoV-2 prevalence using systematic traveller arrival screeningPreprint

Kucharski, A. J., Chung, K., Aubry, M., Teiti, I., Teissier, A., de Soultrait, V. R., Russell, T., Bos, R., Olivier, S., & Cao‐Lormeau, V. (2022) · medRxiv · doi:10.1101/2022.10.12.22280928 · Cited by 1

Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel

Jiang, Q., Zhang, Y. F., & Hu, P. (2022) · JAMA · doi:10.1001/jama.2022.15217 · Cited by 1

Absolute and relative excess mortality across demographic and clinical subgroups during the COVID-19 pandemic: an individual-level cohort study from a nationwide healthcare system of US VeteransPreprint

Weinberger, D. M., Bhaskaran, K., Korves, C., Lucas, B., Columbo, J. A., Vashi, A. A., Davies, L., Justice, A. C., & Rentsch, C. T. (2023) · medRxiv · doi:10.1101/2023.05.12.23289900 · Cited by 1

Leveraging the U.S. blood supply to detect emerging viral threatsPreprint

Justen, L. J., Bhasin, H., Whittaker, C., Cunningham-Bryant, D., Lanteri, M. C., Busch, M. P., Esvelt, K. M., & Sabeti, P. C. (2026) · medRxiv · doi:10.64898/2026.02.06.26345722 · Cited by 1

SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-derived ImmunoglobulinPreprint

Volk, A., Covini-Souris, C., Kuehnel, D., de Mey, C., Römisch, J., & Schmidt, T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.13.456066

Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in Decedents Undergoing Forensic Postmortem Examination: Feasibility for Real-Time Pandemic Surveillance

Coburn, S. B., Manabe, Y. C., Laeyendecker, O. B., Sherman, S. G., Baker, O. R., Quinn, T. C., Graham, L. A., Thomas, F. D., Southall, P. E., Weedn, V. W., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac142

COVID-19 vaccine effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donorsPreprint

Grebe, E., Yu, E. A., Bravo, M. D., Welte, A., Bruhn, R. L., Stone, M., Green, V., Williamson, P. C., Feldstein, L. R., Jones, J. M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1551694/v1

COVID-19 vaccine effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donorsPreprint

Grebe, E., Yu, E. A., Bravo, M. D., Welte, A., Bruhn, R. L., Stone, M., Green, V., Williamson, P. C., Feldstein, L. R., Jones, J. M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1551694/v2

Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020–March 2022, JapanPreprint

Yamayoshi, S., Iwatsuki‐Horimoto, K., Okuda, M., Ujie, M., Yasuhara, A., Murakami, J., Duong, C., Hamabata, T., Ito, M., Chiba, S., et al. (2022) · medRxiv · doi:10.1101/2022.07.11.22277481

Prospective investigation of SARS-CoV-2 seroprevalence in relation to natural infection and vaccination between October 2020 and September 2021 in the Czech RepublicPreprint

Thon, V., Piler, P., Pavlík, T., Andrýsková, L., Doležel, K., Kostka, D., Pikhart, H., Bobák, M., & Klánová, J. (2022) · medRxiv · doi:10.1101/2022.07.21.22277881

Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity Before Coronavirus Disease 2019 Vaccination Among Children 0–4 Years and Their Household Members in the SEARCh Study

Quesada, M. G., Hetrich, M. K., Zeger, S. L., Sharma, J., Na, Y. B., Veguilla, V., Karron, R. A., Dawood, F. S., Knoll, M. D., SEARCh Study Team, et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac507

Estimation of immune response (IgG) to SARS-COV2 (COVID-19) after the third COVID-19 wave in Egypt, A cross-sectional Study

Abdelrahman, M. M., Hemdan, S. B., Farag, R., Eldin, A. N., Khalaf, A., Bakheet, T. M., & Shafik, N. M. (2023) · Egyptian journal of Immunology · doi:10.55133/eji.300104

Trends in Characteristics of Mothers With Confirmed or Presumed COVID-19 During Pregnancy: 14 States and District of Columbia, July 2020–June 2022

Osterman, M. J. K., Martin, J. A., & Valenzuela, C. (2023) · doi:10.15620/cdc:128143

Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020–April 2021

Bosserman, R. E., Farnsworth, C. W., O’Neil, C. A., Cass, C., Park, D., Ballman, C., Wallace, M. A., Struttmann, E. L., Stewart, H. B., Arter, O. G., et al. (2023) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.375

Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in Baltimore, Maryland

Patel, E. U., Mehta, S. H., Genberg, B. L., Baker, O. R., Schluth, C. G., Astemborski, J. A., Fernández, R. E., Quinn, T. C., Kirk, G. D., & Laeyendecker, O. B. (2023) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2023.100184

Silent SARS-CoV-2 infection: seroprevalence study of SARS-CoV-2 anti- nucleocapsid IgG antibodies in Kragujevac, Serbia

Ćićarić, N., Čanović, V., Stojkovic, M., Matic, S. D., Stefanović, S., Popović, S., Todorović, D., Djordjević, N., Radenkovic, B., Radenković, M., et al. (2023) · Acta Virologica · doi:10.3389/av.2023.11996

COVID-19 in a Portuguese whole blood donor population

Fonseca, L., Pereira, F. M., Moura, L. M., Brito, A., Lobo, F., Amaral, A. P., & Costa, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20570

How many is good enough? An analysis of serological follow-up after vaccination against SARS-CoV-2

Stępień, M., Zalewska, M., Kuźniarski, A., Jankowska‐Polańska, B., Piwowar, A., Świątoniowska-Lonc, N., & Knysz, B. (2023) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2023-0020

Associations of Temporal Cardiometabolic Patterns and Incident SARS-CoV-2 Infection Among U.S. Blood Donors With Serologic Evidence of Vaccination

Yu, E. A., Stone, M., Bravo, M. D., Grebe, E., Bruhn, R. L., Lanteri, M. C., Townsend, M., Kamel, H. T., Jones, J. M., Busch, M. P., et al. (2024) · AJPM Focus · doi:10.1016/j.focus.2024.100186

Population-based serosurveys for SARS-CoV-2 transmission 2021-2022, Massachusetts USAPreprint

Cramer, E. Y., Dada, A. O., Onofrey, S., Pearlman, J., Cluverius, J., Loveland, R., Eaton, A., Hatch, M., Harris, L., Dyck, J. J., et al. (2025) · medRxiv · doi:10.1101/2025.01.17.25320194

Low rate of hepatitis Delta virus co‐infection in first‐time blood donors diagnosed with chronic hepatitis B virus infection in the Netherlands

van de Laar, T. J. W., Patmore, L. A., Molier, M., Sonneveld, M. J., Voermans, J. J. C., Slot, E., Feltkamp, M. C. W., van der Eijk, A. A., & Zaaijer, H. L. (2025) · Transfusion · doi:10.1111/trf.18238

Proportions of US Blood Donors With Serological Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections Who Reported Survey-Based Diagnosed Infections During July 2020–December 2022

Akinseye, A., Wright, D. J., Grebe, E., Stone, M., Hathaway, C. A., Fink, R. V., Spencer, B. R., Saá, P., Lanteri, M. C., Busch, M., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf210

Self-Reported SARS-CoV-2 Infections among National Blood Donor Cohort, United States, 2020–2022

Spencer, B. R., Akinseye, A., Grebe, E., Stone, M., Zurita, K. G., Wright, D. J., Haynes, J. M., Stramer, S. L., & Busch, M. P. (2025) · Emerging infectious diseases · doi:10.3201/eid3105.241953

Emerging Adulthood, Health, and Wellbeing

Waite‐Jones, J. M., & Rodriguez, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-88177-0_3

SARS-CoV-2 Seroprevalence, Illness Recall, and Work Absenteeism Among Healthcare Workers: A Facility-Based Cross-Sectional Study in the Philippines, 2021

Subido-Cariño, M. T., Donadel, M., Asi, L. D., Ariola-Ramos, M. S., Arguelles, V. L., Co, S. N., Mahon, G., Fernandez, S., Punzalan, K. A., Sornillo, J. B., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf342

Estimated SARS-CoV-2 Seroprevalence Among Children: United States, September 2021 to December 2022

Bratcher, A. M., Deng, Y., Deng, X., Kim, Y., Coughlin, M. M., Hagen, M. B., Hall, A. J., Swanson, B. E., Meyer, W. A., Gundlapalli, A. V., et al. (2025) · Pediatrics Open Science · doi:10.1542/pedsos.2024-000441

Comparability of Canadian SARS-CoV-2 seroprevalence estimates with statistical adjustment for socio-demographic representation

Yu, Y., Chen, J., Knight, M. J., O’Brien, S. F., Buckeridge, D. L., Charlton, C. L., & Russell, W. A. (2025) · Canadian Journal of Public Health · doi:10.17269/s41997-025-01128-z

Advances and Challenges in AI-Based Biomarker Identification for Pulmonary Diseases: A Comprehensive Review

Benkhalouf, O., Korchiyne, R., Mrhari, A., Ergouyeg, M., Derraz, Y., & Sbai, M. (2026) · Lecture notes in networks and systems · doi:10.1007/978-3-032-03695-7_16

Transfusion requirements in recipients of plasma units from blood donors with recent SARS ‐ CoV ‐2 infection

Roubinian, N. H., Plimier, C., Spencer, B. R., Bravo, M. D., Custer, B. S., D'Alessandro, A., Kleinman, S. H., Norris, P. J., Busch, M. P., & (REDS‐IV), T. N. R. E. A. D. E. S. (2026) · Transfusion · doi:10.1111/trf.70118

Higher uptake of common adult vaccines in Australian blood donors: An analysis of linked registry data

Karki, S., Hoad, V. C., Liu, B. O.-B. Z., Welvaert, M., Hirani, R., & Irving, D. O. (2026) · Vox Sanguinis · doi:10.1111/vox.70205

Blood donor hepatitis B data: An under-recognized surveillance resource in Canada

O’Brien, S. F., Lewin, A., Lee, E. J., & Drews, S. J. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2025-0043

Trends in Coronavirus Disease 2019 Mortality Within a US Academic Health System, 2020–2025

Turner, N., Stout, J. E., & Jenks, J. D. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag138

Seroprevalence of SARS-CoV-2 antibodies among blood donors in Taiwan during the initial COVID-19 surge, April–July 2021

Yen, C.-S., Su, C.-P., Liu, M., Cheng, W., Fang, C., & Chuang, J.-H. (2026) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2026.04.002

Impact of delayed blood donation sample processing and testing on SARS ‐ CoV ‐2 serological assay results in an evolving pandemic response

Lanteri, M. C., Green, V., Sulaeman, H., Stone, M., Haynes, J., Germanio, C. D., Smith, S., Villaflor, P. G., Groves, J. A., Williamson, P. C., et al. (2026) · Transfusion · doi:10.1111/trf.70283

A comparison of alternative vaccination strategies for protecting those vulnerable to illness, hospitalization, or death upon infection with SARS-CoV-2

Feng, Z., Day, T., & Glasser, J. W. (2026) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2026.112531

OA3‐AM23‐ST‐23 | Monitoring Incidence and Seroprevalence of SARS‐CoV‐2 Infections by Vaccine Status Using the US Nationwide Blood Donor Cohort

Jones, J. M., Stone, M., Grebe, E., Saá, P., Germanio, C. D., Manrique, I. M., Lanteri, M. C., Stramer, S. L., Opsomer, J. D., & Busch, M. P. (2023) · Transfusion · doi:10.1111/trf.30_17554 · Cited by 1

Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program

Stone, M., Germanio, C. D., Wright, D. J., Sulaeman, H., Dave, H., Fink, R. V., Notari, E. P., Green, V., Strauss, D., Kessler, D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab537 · Cited by 45

Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study

Lewin, A., Serres, G. D., Grégoire, Y., Perreault, J., Drouin, M., Fournier, M., Tremblay, T., Beaudoin, J., Boivin, A., Goyette, G., et al. (2022) · Canadian Journal of Public Health · doi:10.17269/s41997-022-00622-y · Cited by 8

Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021

Busch, M. P., Stramer, S. L., Stone, M., Yu, E. A., Grebe, E., Notari, E. P., Saá, P., Ferg, R., Manrique, I. M., Weil, N., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac470 · Cited by 30

Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status — United States, April 2021–September 2022

Jones, J. M., Manrique, I. M., Stone, M., Grebe, E., Saá, P., Germanio, C. D., Spencer, B. R., Notari, E. P., Bravo, M. D., Lanteri, M. C., et al. (2023) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7222a3 · Cited by 141